# Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

> **NCT00758693** · PHASE2 · WITHDRAWN · sponsor: **University of Kentucky**

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00758693
- **Lead sponsor:** University of Kentucky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-10
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding was withdrawn due to insufficient accrual
- **Last updated:** 2012-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758693, "Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00758693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*